USPTO Examiner GILL RACHEL B - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19350804LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYOctober 2025January 2026Allow310NoNo
19350928LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYOctober 2025January 2026Allow310NoNo
19183257SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINESApril 2025November 2025Allow710YesNo
19014949LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYJanuary 2025July 2025Allow610NoNo
18742986METHODS AND PRODUCTS FOR GENETIC ENGINEERINGJune 2024March 2025Allow910YesNo
17270341BINDING PROTEIN OF NS1 PROTEINApril 2024February 2025Allow4720NoNo
18440735IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAMEFebruary 2024September 2025Abandon1910NoNo
18440344ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTIONFebruary 2024May 2025Allow1511NoNo
18435026MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXESFebruary 2024April 2025Allow1411YesNo
18416835VARICELLA ZOSTER VIRUS (VZV) VACCINEJanuary 2024September 2025Allow2010YesNo
18515358GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPYNovember 2023August 2025Allow2120NoNo
18509781METHODS FOR ANALYSIS OF VIRAL CAPSID PROTEIN COMPOSITIONNovember 2023July 2025Allow2020NoNo
18506578HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDENovember 2023June 2025Allow1910NoNo
18496076Recombinant Cytomegalovirus Vectors As Vaccines For TuberculosisOctober 2023June 2025Allow1920NoNo
18488604METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORSOctober 2023February 2025Abandon1601NoNo
18481204HERPES SIMPLEX VIRUS VACCINEOctober 2023March 2025Abandon1710NoNo
18474014METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEINSeptember 2023April 2025Allow1910NoNo
18458657LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYAugust 2023September 2024Allow1320YesNo
18452624MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIESAugust 2023June 2025Allow2220NoNo
18232437VETO CELLS GENERATED FROM MEMORY T CELLSAugust 2023April 2025Allow2010NoNo
18365948NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)August 2023July 2025Abandon2350YesNo
18358350EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTSJuly 2023January 2025Allow1811YesNo
18354849Use of Triplex CMV Vaccine in CAR T Cell TherapyJuly 2023July 2025Allow2420NoYes
18355265DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTSJuly 2023September 2024Allow1410NoNo
18354574HERPES SIMPLEX VIRUS VACCINEJuly 2023March 2025Abandon2010NoNo
18351392COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSESJuly 2023April 2025Allow2120NoNo
18345893CORONAVIRUS VACCINE COMPOSITIONS AND METHODSJune 2023September 2024Allow1510YesNo
18342284COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKINJune 2023November 2025Allow2920YesNo
18342666SCALABLE PURIFICATION METHOD FOR AAV9June 2023August 2025Allow2520NoYes
18335810HBV VACCINES AND METHODS TREATING HBVJune 2023May 2025Allow2321YesNo
18334279MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTIONJune 2023July 2024Allow1310NoNo
18333718SCALABLE PURIFICATION METHOD FOR AAV1June 2023July 2024Allow1310NoNo
18200997ANTIGEN DELIVERY PLATFORMSMay 2023December 2024Abandon1910NoNo
18318061VACCINES AGAINST ZIKA VIRUSMay 2023May 2025Allow2420YesNo
18141055Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA VirusesApril 2023January 2025Abandon2010NoNo
18297207SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDSApril 2023January 2025Abandon2110NoNo
18130375METHODS AND PRODUCTS FOR GENETIC ENGINEERINGApril 2023September 2024Allow1810YesNo
18189512RESPIRATORY VIRUS NUCLEIC ACID VACCINESMarch 2023December 2024Abandon2110NoNo
18183066TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOFMarch 2023December 2024Abandon2110NoNo
18182212MEANS AND METHODS FOR TREATING HERPESVIRUS INFECTIONMarch 2023May 2025Allow2620NoNo
18176014NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)February 2023November 2024Abandon2020NoNo
18023580VACCINE COMPOSITION FOR CHICKENPOX OR VARICELLA ZOSTER AND METHOD OF USING SAMEFebruary 2023October 2025Allow3200YesNo
18165770ONCOLYTIC VIRAL VECTORS AND USES THEREOFFebruary 2023October 2024Allow2010YesNo
18004065POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOFJanuary 2023March 2026Abandon3801NoNo
18012879KIT AND METHODS FOR CHARACTERIZING A VIRUS IN A SAMPLEDecember 2022February 2026Abandon3810NoNo
18012343COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUSDecember 2022March 2026Abandon3910NoNo
18145136VARICELLA ZOSTER VIRUS VACCINEDecember 2022December 2025Abandon3630NoNo
18060386STABLE FORMULATIONS OF CYTOMEGALOVIRUSNovember 2022March 2025Abandon2730NoNo
18071109HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USENovember 2022July 2024Allow2020NoNo
17925988VIRAL VACCINE VECTOR FOR IMMUNIZATION AGAINST A BETACORONAVIRUSNovember 2022January 2026Abandon3810NoNo
17998737RECOMBINANT VACCINE AGAINST COVID-19 BASED ON A PARAMYXOVIRUS VIRAL VECTORNovember 2022December 2025Allow3710YesNo
17938823ZOONOTIC DISEASE RNA VACCINESOctober 2022June 2025Abandon3230NoNo
17950308MULTIPLEXED LATERAL FLOW ASSAY FOR DETECTION OF HPV ASSOCIATED CANCERSeptember 2022November 2025Allow3810NoNo
17802001CORONAVIRUS VACCINESAugust 2022December 2025Abandon3910NoNo
17816060DIAGNOSIS OF CONGENITAL CYTOMEGALOVIRUS INFECTIONJuly 2022August 2025Allow3610NoNo
17812732RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOFJuly 2022April 2025Allow3340YesNo
17855571AAV VECTOR AND ASSAY FOR ANTI-AAV (ADENO-ASSOCIATED VIRUS) NEUTRALIZING ANTIBODIESJune 2022November 2025Abandon4150NoNo
17852891EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICSJune 2022December 2024Allow2920YesNo
17846296EPSTEIN-BARR VIRUS NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAMEJune 2022October 2025Allow4060NoNo
17840478HUMAN CYTOMEGALOVIRUS VACCINEJune 2022November 2024Abandon2930NoNo
17779011METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) AND MEASURING AND QUANTIFYING PENTAMERIC COMPLEX USING AN INDIRECT SANDWICH ELISAMay 2022January 2026Abandon4420NoNo
17773277ONCOLYTIC VIROTHERAPY WITH INDUCED ANTI-TUMOR IMMUNITYApril 2022December 2025Abandon4410NoNo
17771595NOVEL ANTIBODIES FOR DETECTING EPSTEIN BARR VIRUS-POSITIVE GASTRIC CANCERApril 2022December 2025Allow4410YesNo
17714307MODIFIED VIRUS-LIKE PARTICLES OF CMVApril 2022December 2025Allow4430YesNo
17638344HEPATITIS B VIRUS VACCINESFebruary 2022September 2025Allow4310YesNo
17670052COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUSFebruary 2022June 2025Allow4010NoNo
17631808COMBINATION DRUG FOR TREATING MALIGNANT TUMOR, PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOR, AND PHARMACEUTICAL COMPOSITION FOR MALIGNANT TUMOR TREATMENTJanuary 2022October 2025Abandon4510NoNo
17628351MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINSJanuary 2022June 2025Allow4110NoNo
17577681METHODS AND COMPOSITIONS FOR TREATING INFECTIONSJanuary 2022October 2024Allow3310NoNo
17553561Method and Apparatus for Rapid Virus Screening and Detection using a CanineDecember 2021September 2025Abandon4510NoNo
17535121VACCINES AGAINST HEPATITIS B VIRUSNovember 2021September 2025Abandon4640NoYes
17595124MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEINNovember 2021February 2026Allow5130YesNo
17510969VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORMOctober 2021June 2025Allow4410NoNo
17604072Adeno-Associated Virus Vector Formulations and MethodsOctober 2021November 2025Abandon4910NoNo
17475001VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOFSeptember 2021March 2025Allow4230NoNo
17407716MODIFIED CAPSID PROTEINS FOR ENHANCED DELIVERY OF PARVOVIRUS VECTORSAugust 2021February 2025Allow4140NoYes
17431856MULTIVALENT KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS-LIKE PARTICLES AND USES THEREOFAugust 2021July 2024Allow3510YesNo
17420529PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORSJuly 2021May 2025Abandon4620NoNo
17322054BIOMATERIAL-BASED COVID-19 VACCINEMay 2021October 2025Abandon5350NoNo
17300287REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFOREMay 2021November 2024Allow4240NoNo
17290384RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAMEApril 2021April 2025Allow4710NoNo
17287698CANINE DISTEMPER VACCINES AND METHODS OF TREATMENT USING THE SAMEApril 2021April 2025Allow4830NoNo
17231534VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANTApril 2021July 2024Allow4030YesNo
17280803RECOMBINANT VIRAL VECTOR, IMMUNE COMPOSITION CONTAINING SAME, AND USE THEREOFMarch 2021September 2024Allow4120NoNo
17279501COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASESMarch 2021February 2026Allow5930NoNo
17273977Storage Improved Poxvirus CompositionsMarch 2021July 2024Allow4120NoNo
17272096NS1-BINDING PROTEINFebruary 2021January 2025Allow4720YesNo
17272158NS1-BINDING PROTEINFebruary 2021April 2025Allow5020NoNo
17271287Recombinant Replication Competent Viruses Comprising a Coding Region for Glycogen Synthase Kinase-3 (GSK3) and Methods of Killing Aberrant CellsFebruary 2021December 2024Allow4620NoNo
17269409VACCINES AGAINST NIPAH VIRUS, AND METHODS OF USING SAMEFebruary 2021March 2025Allow4930NoNo
17266827A VIRUS NEUTRALIZATION ASSAY UTILIZING IMAGING CYTOMETRYFebruary 2021September 2025Allow5530NoNo
17264377METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINEJanuary 2021February 2025Abandon4830YesNo
17255517INFLUENZA VIRUS HEMAGGLUTININ MUTANTSDecember 2020May 2025Allow5321YesNo
17095318MVA VECTORS FOR EXPRESSING MULTIPLE CYTOMEGALOVIRUS (CMV) ANTIGENS AND USE THEREOFNovember 2020September 2025Allow5850YesNo
17091756FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUSNovember 2020November 2024Allow4840NoNo
16982039VACCINE COMPOSITIONSSeptember 2020May 2025Allow5640NoNo
16888398IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORMEMay 2020January 2025Abandon5530NoYes
16765285EPSTEIN-BARR VIRUS VACCINESMay 2020May 2025Abandon6070NoNo
16762286PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION COMPRISING SIZING OF LIPID VESICLE PARTICLES, AND USES THEREOFMay 2020February 2025Abandon5740NoNo
16741827ENGINEERED HERPES SIMPLEX VIRUS-1 (HSV-1) VECTORS AND USES THEREOFJanuary 2020September 2024Allow5640NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GILL, RACHEL B.

Strategic Value of Filing an Appeal

Total Appeal Filings
8
Allowed After Appeal Filing
1
(12.5%)
Not Allowed After Appeal Filing
7
(87.5%)
Filing Benefit Percentile
15.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GILL, RACHEL B - Prosecution Strategy Guide

Executive Summary

Examiner GILL, RACHEL B works in Art Unit 1671 and has examined 85 patent applications in our dataset. With an allowance rate of 85.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner GILL, RACHEL B's allowance rate of 85.9% places them in the 63% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GILL, RACHEL B receive 2.47 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GILL, RACHEL B is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.5% benefit to allowance rate for applications examined by GILL, RACHEL B. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 51.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.